NZ725028A - Membrane-adherent self-assembled systems for treatment of ocular disorders - Google Patents

Membrane-adherent self-assembled systems for treatment of ocular disorders

Info

Publication number
NZ725028A
NZ725028A NZ725028A NZ72502815A NZ725028A NZ 725028 A NZ725028 A NZ 725028A NZ 725028 A NZ725028 A NZ 725028A NZ 72502815 A NZ72502815 A NZ 72502815A NZ 725028 A NZ725028 A NZ 725028A
Authority
NZ
New Zealand
Prior art keywords
delivery system
present
liquid crystalline
alcohol
nanoparticles
Prior art date
Application number
NZ725028A
Other languages
English (en)
Inventor
Shikha P Barman
Ritesh V Thekkedath
Koushik Barman
Kevin L Ward
Anne-Marie Cromwick
Original Assignee
Integral Biosystems Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integral Biosystems Llc filed Critical Integral Biosystems Llc
Publication of NZ725028A publication Critical patent/NZ725028A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
NZ725028A 2014-05-01 2015-05-01 Membrane-adherent self-assembled systems for treatment of ocular disorders NZ725028A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461987012P 2014-05-01 2014-05-01
PCT/US2015/028748 WO2015168523A1 (en) 2014-05-01 2015-05-01 Membrane-adherent self-assembled systems for treatment of ocular disorders

Publications (1)

Publication Number Publication Date
NZ725028A true NZ725028A (en) 2019-01-25

Family

ID=54359368

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ725028A NZ725028A (en) 2014-05-01 2015-05-01 Membrane-adherent self-assembled systems for treatment of ocular disorders

Country Status (12)

Country Link
US (2) US9901544B2 (ko)
EP (1) EP3137481B1 (ko)
JP (1) JP6452725B2 (ko)
KR (1) KR101890503B1 (ko)
CN (1) CN106459137B (ko)
AU (2) AU2015252908B2 (ko)
CA (1) CA2946373C (ko)
ES (1) ES2924768T3 (ko)
MY (1) MY193694A (ko)
NZ (1) NZ725028A (ko)
SG (1) SG11201608729RA (ko)
WO (1) WO2015168523A1 (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3266446B1 (en) * 2016-07-07 2018-11-21 Laboratorios SALVAT, S.A. Ophthalmic composition comprising castor oil and medium chain triglyceride
WO2018230713A1 (ja) * 2017-06-16 2018-12-20 学校法人同志社 カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用
CN110944668A (zh) 2017-06-16 2020-03-31 学校法人同志社 用于治疗或预防眼部症状、障碍或疾病的包含mTOR抑制剂的药物及其应用
EP3643297A4 (en) * 2017-06-22 2021-03-17 Yonsung Fine Chemical Co., Ltd. OPHTHALMIC COMPOSITION FOR GLUCOMA TREATMENT
US11129862B2 (en) 2017-08-30 2021-09-28 Johnson & Johnson Consumer Inc. Ophthalmic compositions
JP7056480B2 (ja) * 2017-09-08 2022-04-19 ライオン株式会社 眼科用組成物及び涙液油層安定化剤
CN109316440B (zh) * 2018-09-29 2020-12-29 华中科技大学 一种温敏性液晶纳米水凝胶及其制备方法与应用
WO2020084530A1 (en) * 2018-10-24 2020-04-30 Ferring B.V. Mucoadhesive pharmaceutical compositions of corticosteroids
GB201818043D0 (en) * 2018-11-05 2018-12-19 Waterford Institute Of Tech Artifical Tears
US20210353554A1 (en) * 2020-05-18 2021-11-18 Max Biology Co. Ltd. Lipid-polymer compositions and methods of use
US12016855B2 (en) 2020-08-26 2024-06-25 Somerset Therapeutics, Llc Prednisolone and moxifloxacin compositions and methods
WO2022077060A1 (en) * 2020-10-13 2022-04-21 University Of South Australia Antimicrobial compositions and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716830B2 (en) * 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
JP4049216B2 (ja) * 2003-05-09 2008-02-20 ポーラ化成工業株式会社 液晶構造を有する製剤
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20050235740A1 (en) * 2004-04-27 2005-10-27 Guido Desie Method to improve the quality of dispersion formulations
WO2006009825A1 (en) * 2004-06-17 2006-01-26 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
WO2006062875A1 (en) * 2004-12-08 2006-06-15 Merck & Co., Inc. Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor
CN101137370B (zh) * 2005-02-09 2014-08-13 参天制药株式会社 用于治疗疾病或病症的液体制剂
US8906392B2 (en) * 2005-12-16 2014-12-09 University Of Kansas Nanocluster compositions and methods
KR20090053892A (ko) * 2006-07-25 2009-05-28 오스모티카 코프. 점안액
JP2010064995A (ja) * 2008-09-12 2010-03-25 Nikko Chemical Co Ltd 外用消炎鎮痛剤組成物
JP5207420B2 (ja) * 2009-12-25 2013-06-12 株式会社ケムジェネシス 低粘度液晶化合物
CN101773670A (zh) * 2009-12-29 2010-07-14 中山大学 一种液晶药物载体
JP2012017318A (ja) * 2010-06-07 2012-01-26 Nikko Chemical Co Ltd 液晶及びそれを含有する皮膚外用剤
US8772273B2 (en) * 2011-10-04 2014-07-08 Quretino Therapeutics, Inc. Formulations and uses of retinoic acid receptor selective agonists
MX2014013315A (es) * 2012-05-03 2015-09-10 Kala Pharmaceuticals Inc Nanoparticulas farmaceuticas que muestran la mejora del transporte de la mucosa.
PT3517541T (pt) * 2012-05-08 2020-08-28 Nicox Ophthalmics Inc Forma polimórfica de propionato de fluticasona
US8765725B2 (en) * 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof

Also Published As

Publication number Publication date
CA2946373A1 (en) 2015-11-05
US9901544B2 (en) 2018-02-27
KR20160147784A (ko) 2016-12-23
SG11201608729RA (en) 2016-11-29
CN106459137A (zh) 2017-02-22
AU2018201596A1 (en) 2018-03-29
US20180185275A1 (en) 2018-07-05
ES2924768T3 (es) 2022-10-10
JP6452725B2 (ja) 2019-01-16
EP3137481A1 (en) 2017-03-08
EP3137481A4 (en) 2017-12-27
EP3137481B1 (en) 2022-07-06
KR101890503B1 (ko) 2018-08-21
US20170049697A1 (en) 2017-02-23
AU2018201596B2 (en) 2020-02-06
JP2017514843A (ja) 2017-06-08
CA2946373C (en) 2018-07-31
US10603273B2 (en) 2020-03-31
MY193694A (en) 2022-10-25
WO2015168523A1 (en) 2015-11-05
CN106459137B (zh) 2019-04-12
AU2015252908A1 (en) 2016-10-27
AU2015252908B2 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
NZ725028A (en) Membrane-adherent self-assembled systems for treatment of ocular disorders
MX2020012041A (es) Formulacion farmaceutica.
US11376275B2 (en) Ophthalmic compositions with improved dessication protection and retention
JP6832390B2 (ja) 水性液剤
PH12019550088A1 (en) Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
JP7055930B2 (ja) 眼科組成物
CN102784416A (zh) 一种新型助分娩凝胶及其制备方法和应用
RU2017146716A (ru) Способ образования наночастиц циклоспорина а/ циклодекстрина
KR20170036058A (ko) 코 적용을 위한 시네올-함유 조성물
JP4751482B2 (ja) コンタクトレンズ用液剤
JP2006225323A (ja) 水性外用組成物
JP2006248960A (ja) 水性外用組成物
JP2022079633A (ja) 異物感改善用眼科組成物
EP3494970A3 (en) Hardly soluble therapeutic agents belonging to bcs class ii or iv suspended in the liquid formulation and/or in the final nanofibrous structure
CN102772426A (zh) 壳聚糖作为助分娩润滑剂成分的医药用途
JP6077860B2 (ja) 液剤
JP2017119693A (ja) 眼科用組成物及びその製造方法
JP2006206481A (ja) 水性外用組成物
JP6333023B2 (ja) 水性医薬組成物
JP6571391B2 (ja) 水性製剤
CN104606682A (zh) 一种更昔洛韦眼用制剂及其制备方法
GR1008261B (el) Συνθεσεις νανοφορεων
GR1008332B (el) Συνθεσεις νανοφορεων
CN105232456A (zh) 丙酸聚六亚甲基胍滴眼液
UA80243U (ru) Система доставки лекарств

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE INVENTOR HAS BEEN CORRECTED TO 3540134, BARMAN, SHIKHA P., 2 BONNIEVALE DRIVEBEDFORD, MASSACHUSETTS 01730, US; 3540135, THEKKEDATH, RITESH V., 335 HUNTINGTON AVENUE, APT #21BOSTON, MASSACHUSETTS 02115, US; 3546668, BARMAN, KOUSHIK, 2 BONNIEVALE DR., BEDFORD, MASSACHUSETTS 01730, US; 3546669, WARD, KEVIN L., 106 CLEREMON AVE., ARLINGTON, MASSACHUSETTS 02476, US; 3546670, CROMWICK, ANNE-MARIE, 11 DONNA RD., SAUGUS, MASSACHUSETTS 01906, US

Effective date: 20161125

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAY 2021 BY COMPUTER PACKAGES INC

Effective date: 20200418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAY 2022 BY COMPUTER PACKAGES INC

Effective date: 20210418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAY 2023 BY COMPUTER PACKAGES INC

Effective date: 20220417

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAY 2024 BY COMPUTER PACKAGES INC

Effective date: 20230417